Compare International Business Machines Corp (IBM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Business Machines Corp vs Recursion Pharmaceuticals Inc — how do they compare? International Business Machines Corp trades at $226.09 (market cap $207.75B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: International Business Machines Corp is far larger — about 89.9× Recursion Pharmaceuticals Inc's market cap, and International Business Machines Corp pays a 3.07% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold International Business Machines Corp for 88 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| IBM | RXRX | |
|---|---|---|
Market Cap | $207.75B | $2.31B |
Volume | 3,864,661 | 40,478,768 |
Sector | Technology | Health |
52-Week High | $329.23 | $6.79 |
52-Week Low | $205.77 | $2.84 |
Typical Hold Time | 88 Days | 22 Days |
Enterprise Value | $264.89B | $1.83B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBM's stock trades at $220.51, down 0.35% on the day, amid a bearish technical signal. The company reported strong 2025 results with revenue of $67.54B and net income of $10.59B, beating earnings expectations in recent quarters. Analyst consensus is a Buy with a $256.69 price target, though technical indicators show resistance near $222. Recent news highlights IBM's focus on AI, including self-hosted deployment for its Bob platform.
IBM presents a mixed outlook with solid fundamentals and AI growth potential offset by near-term technical weakness and competitive pressures. The stock's valuation appears reasonable with a P/E of 19.58, but investors face risks from execution challenges and market volatility. Upside hinges on sustained earnings growth and successful AI integration.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
